Skip to main content

Compare Stocks

Date Range: 

 ADC TherapeuticsMyovant SciencesHeron TherapeuticsHarmony BiosciencesAurinia Pharmaceuticals
SymbolNYSE:ADCTNYSE:MYOVNASDAQ:HRTXNASDAQ:HRMYNASDAQ:AUPH
Price Information
Current Price$21.23$21.26$13.85$27.88$11.92
52 Week RangeBuyHoldBuyBuyBuy
MarketRank™
Overall Score1.71.31.71.41.8
Analysis Score3.43.23.43.53.5
Community Score3.72.62.72.13.0
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.70.82.5
Earnings & Valuation Score0.60.60.60.60.0
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$48.75$31.57$27.50$51.67$28.00
% Upside from Price Target129.63% upside48.50% upside98.56% upside85.32% upside134.90% upside
Trade Information
Market Cap$1.46 billion$1.94 billion$1.41 billion$1.59 billion$1.53 billion
BetaN/A2.991.52N/A0.87
Average Volume327,737893,0821,247,234135,9854,495,613
Sales & Book Value
Annual Revenue$2.34 millionN/A$145.97 millionN/A$320,000.00
Price / Sales625.03N/A9.66N/A4,772.51
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/A($1.21) per share$4.48 per shareN/A$2.45 per share
Price / BookN/A3.09N/A4.87
Profitability
Net Income$-116,480,000.00$-288,990,000.00$-204,750,000.00N/A$-123,850,000.00
EPS($2.36)($3.37)($2.50)N/A($0.89)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/A24.03N/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-216.18%N/A-173,992.23%
Return on Equity (ROE)N/AN/A-65.06%N/A-36.98%
Return on Assets (ROA)N/A-201.20%-49.14%N/A-31.06%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.28%N/AN/A2.04%N/A
Current Ratio15.55%1.75%3.60%7.87%17.23%
Quick Ratio15.55%1.75%3.16%7.80%16.95%
Ownership Information
Institutional Ownership Percentage40.88%33.77%99.01%50.17%51.21%
Insider Ownership PercentageN/A3.90%12.85%N/AN/A
Miscellaneous
Employees208214223150294
Shares Outstanding68.89 million91.48 million101.83 million56.90 million128.12 million
Next Earnings Date8/17/2021 (Estimated)8/10/2021 (Estimated)8/4/2021 (Estimated)8/10/2021 (Estimated)8/10/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Aurinia Pharmaceuticals (AUPH) Receives a Buy from Leerink PartnersAurinia Pharmaceuticals (AUPH) Receives a Buy from Leerink Partners
smarteranalyst.com - May 13 at 9:42 AM
Peter Greenleaf Acquires 5,125 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) StockPeter Greenleaf Acquires 5,125 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock
americanbankingnews.com - May 12 at 6:10 PM
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Jill Leversage Acquires 2,500 SharesAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Jill Leversage Acquires 2,500 Shares
americanbankingnews.com - May 12 at 6:10 PM
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) VP Matthew Maxwell Donley Buys 9,900 SharesAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) VP Matthew Maxwell Donley Buys 9,900 Shares
americanbankingnews.com - May 12 at 5:26 PM
-$0.33 Earnings Per Share Expected for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) This Quarter-$0.33 Earnings Per Share Expected for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) This Quarter
americanbankingnews.com - May 11 at 3:16 PM
Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 10.1% Higher Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 10.1% Higher
americanbankingnews.com - May 11 at 12:46 PM
Aurinia Pharmaceuticals Inc. [AUPH] Stock trading around $10.15 per share: What’s Next?Aurinia Pharmaceuticals Inc. [AUPH] Stock trading around $10.15 per share: What’s Next?
dbtnews.com - May 10 at 4:03 PM
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q1 2021 Results - Earnings Call TranscriptAurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 6:06 PM
Aurinia Pharmaceuticals (NASDAQ:AUPH) Issues  Earnings ResultsAurinia Pharmaceuticals (NASDAQ:AUPH) Issues Earnings Results
americanbankingnews.com - May 8 at 12:40 PM
Aurinia Pharma EPS misses by $0.02, misses on revenueAurinia Pharma EPS misses by $0.02, misses on revenue
seekingalpha.com - May 8 at 8:05 AM
Analysts Say Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Can Really Get to $35 in 12 MonthsAnalysts Say Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Can Really Get to $35 in 12 Months
marketingsentinel.com - May 7 at 3:13 PM
Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 1-Year Low at $10.20Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 1-Year Low at $10.20
americanbankingnews.com - May 7 at 11:08 AM
Oppenheimer Reaffirms Buy Rating for Aurinia Pharmaceuticals (NASDAQ:AUPH)Oppenheimer Reaffirms Buy Rating for Aurinia Pharmaceuticals (NASDAQ:AUPH)
americanbankingnews.com - May 7 at 7:00 AM
Aurinia: Q1 Earnings SnapshotAurinia: Q1 Earnings Snapshot
sfgate.com - May 6 at 11:05 PM
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational HighlightsAurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
finance.yahoo.com - May 6 at 6:05 PM
Why Aurinia Pharmaceuticals Stock Is Crashing TodayWhy Aurinia Pharmaceuticals Stock Is Crashing Today
finance.yahoo.com - May 6 at 6:05 PM
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $12.27Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $12.27
americanbankingnews.com - May 6 at 1:34 PM
Thinking about buying stock in Arlo Technologies, Evolus, Nikola Corp, Aurinia Pharmaceuticals, or Celsion Corp?Thinking about buying stock in Arlo Technologies, Evolus, Nikola Corp, Aurinia Pharmaceuticals, or Celsion Corp?
benzinga.com - May 6 at 1:04 PM
Aurinia Pharmaceuticals Inc. to Post FY2022 Earnings of ($0.45) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:AUPH)Aurinia Pharmaceuticals Inc. to Post FY2022 Earnings of ($0.45) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:AUPH)
americanbankingnews.com - May 6 at 11:40 AM
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $12.08Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $12.08
americanbankingnews.com - April 30 at 10:44 AM
Leerink Partners Stick to Their Buy Rating for Aurinia PharmaceuticalsLeerink Partners Stick to Their Buy Rating for Aurinia Pharmaceuticals
investing.com - April 30 at 1:59 AM
Aurinia Pharmaceuticals (AUPH) to Release Earnings on ThursdayAurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday
americanbankingnews.com - April 29 at 8:16 AM
Are Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Ready For A Higher Price Run?Are Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Ready For A Higher Price Run?
marketingsentinel.com - April 28 at 1:48 PM
Zacks Investment Research Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to SellZacks Investment Research Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to Sell
marketbeat.com - April 27 at 6:15 PM
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Down 5%Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Down 5%
americanbankingnews.com - April 27 at 3:46 PM
Aurinia Pharmaceuticals Inc (AUPH)Aurinia Pharmaceuticals Inc (AUPH)
investing.com - April 25 at 12:33 PM
DateCompanyBrokerageAction
5/14/2021ADC TherapeuticsHC WainwrightLower Price Target
5/10/2021ADC TherapeuticsMorgan StanleyLower Price Target
12/2/2020ADC TherapeuticsStifel NicolausInitiated Coverage
6/9/2020ADC TherapeuticsCowenInitiated Coverage
6/9/2020ADC TherapeuticsBank of AmericaInitiated Coverage
5/13/2021Myovant SciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
5/3/2021Myovant SciencesJPMorgan Chase & Co.Lower Price Target
2/12/2021Myovant SciencesSVB LeerinkLower Price Target
1/6/2021Myovant SciencesThe Goldman Sachs GroupDowngrade
12/21/2020Myovant SciencesRobert W. BairdBoost Price Target
6/23/2020Myovant SciencesEvercore ISIBoost Price Target
11/19/2019Myovant SciencesJMP SecuritiesReiterated Rating
8/6/2020Heron TherapeuticsNorthland SecuritiesInitiated Coverage
5/26/2020Heron TherapeuticsGuggenheimInitiated Coverage
5/18/2020Heron TherapeuticsFIXInitiated Coverage
4/15/2020Heron TherapeuticsNeedham & Company LLCReiterated Rating
2/20/2020Heron TherapeuticsCantor FitzgeraldReiterated Rating
9/14/2020Harmony BiosciencesJefferies Financial GroupInitiated Coverage
9/14/2020Harmony BiosciencesPiper SandlerInitiated Coverage
5/7/2021Aurinia PharmaceuticalsBloom BurtonUpgrade
5/7/2021Aurinia PharmaceuticalsRoyal Bank of CanadaLower Price Target
5/7/2021Aurinia PharmaceuticalsOppenheimerReiterated Rating
6/16/2020Aurinia PharmaceuticalsBTIG ResearchInitiated Coverage
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.